1. Home
  2. HOMB vs RYTM Comparison

HOMB vs RYTM Comparison

Compare HOMB & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Home BancShares Inc.

HOMB

Home BancShares Inc.

SELL

Current Price

$29.87

Market Cap

5.7B

Sector

Finance

ML Signal

SELL

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

SELL

Current Price

$107.44

Market Cap

6.3B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
HOMB
RYTM
Founded
1998
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7B
6.3B
IPO Year
2006
2017

Fundamental Metrics

Financial Performance
Metric
HOMB
RYTM
Price
$29.87
$107.44
Analyst Decision
Buy
Strong Buy
Analyst Count
10
19
Target Price
$32.88
★ $140.12
AVG Volume (30 Days)
1.5M
★ 1.6M
Earning Date
10-14-2026
11-03-2026
Dividend Yield
★ 3.07%
N/A
EPS Growth
19.90
★ 28.34
EPS
★ 1.84
N/A
Revenue
N/A
N/A
Revenue This Year
$4.28
$73.80
Revenue Next Year
$3.19
$73.86
P/E Ratio
$16.31
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.50
$74.50
52 Week High
$31.70
$122.20

Technical Indicators

Market Signals
Indicator
HOMB
RYTM
Relative Strength Index (RSI) 49.66 57.44
Support Level $29.70 $106.58
Resistance Level $30.32 $111.16
Average True Range (ATR) 0.57 6.96
MACD -0.05 1.57
Stochastic Oscillator 19.84 74.77

Price Performance

Historical Comparison
HOMB
RYTM

About HOMB Home BancShares Inc.

Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The company has one reportable segment: The Banking Segment.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: